In This Article:
BASF SE’s BASFY Aroma Ingredients brand, Isobionics, is set to launch two new natural ingredients, Isobionics Natural beta-Sinensal 20 and Isobionics Natural alpha-Humulene 90, for the flavor market. These are produced using a cutting-edge fermentation process. Isobionics Natural alpha-Humulene 90 is geared for applications in beverages and essential oils.
BASF has been investing in innovations and the launch of these products is a part of this effort. The Isobionics Natural beta-Sinensal 20 has a potential for wide use in savory formulations, adding juiciness to any flavour or enhancing the organoleptic properties of orange oil products. The Isobionics Natural alpha-Humulene 90 is a woody flavor ingredient with high purity and is suitable for non-alcoholic as well as alcoholic beverages. This is a perfect choice for hop oil applications.
The manufacturing process of both ingredients entails fermentation from readily available renewable raw materials and is independent from weather and harvest conditions, enabling consistent premium quality as well as reliable availability. BASF’s dedicated team for Specialty Aroma Ingredients has been continuously driving such product innovations to keep up with current and future trends.
BASFY stock has lost 7.9% in the past year compared with the 16.6% decline in the industry.
Image Source: Zacks Investment Research
BASFY’s Zacks Rank and Key Picks
BASFY currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Ingevity Corporation NGVT, Axalta Coating Systems AXTA and Carpenter Technology Corporation CRS. While NGVT and AXTA sport a Zacks Rank #1 (Strong Buy) each at present, CRS carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Ingevity’s current-year earnings is pegged at $4.45 per share. NGVT’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with the average surprise being 202.9%.
The Zacks Consensus Estimate for Axalta’s current-year earnings is pegged at $2.51 per share. AXTA’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 16.28%.
The Zacks Consensus Estimate for Carpenter Technology’s current fiscal-year earnings is pegged at $6.95 per share. CRS’ earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 15.7%. Its shares have soared 169.5% in the past year.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report